What topics does this cannabis study cover?

This study covers research on: Epilepsy, Neuroprotection.

Where was this research published?

Published in Expert opinion on pharmacotherapy on June 3, 2026.

CBD emerges as seizure treatment option in rare genetic disorder

Q: What did this Review find?

Angelman syndrome (AS) is a rare **neurodevelopmental disorder** affecting brain development and function, characterized by intellectual disability, absent speech, difficulty with movement (ataxic gait), and **seizures in 80-90% of patients**. The condition arises from loss of maternal *UBE3A* gene

How I treat angleman syndrome: an expert opinion.

Expert opinion on pharmacotherapy • June 3, 2026 • Review • Moderately Relevant

🤖

AI Summary

Angelman syndrome (AS) is a rare neurodevelopmental disorder affecting brain development and function, characterized by intellectual disability, absent speech, difficulty with movement (ataxic gait), and seizures in 80-90% of patients. The condition arises from loss of maternal UBE3A gene function. This expert review provides comprehensive clinical guidance on managing AS, covering everything from initial diagnosis through lifelong care, with particular emphasis on controlling seizures, which represent the most disabling feature for most patients and their families.

The current standard treatment approach focuses on symptomatic seizure management rather than curing the underlying genetic defect. Levetiracetam and clobazam are the preferred first-line medications, while valproate and clonazepam remain effective but carry more complex side effects. The review notably mentions emerging reports of cannabidiol (CBD) oil use as a treatment option, reflecting growing clinical interest in cannabinoid-based therapies for seizure management in AS. Additional non-pharmaceutical approaches include the ketogenic diet and low glycemic index diets, which can help manage refractory seizures when medications alone are insufficient.

A major paradigm shift is underway, with three antisense oligonucleotide programs and the first gene replacement therapy now entering Phase 2/3 clinical trials. These represent potential disease-modifying therapies that could address the root genetic cause rather than just symptoms. The review emphasizes the critical importance of multidisciplinary, lifelong care and acknowledges the significant burden placed on caregivers, positioning comprehensive support as essential to patient outcomes.

📄 Original Abstract

Angelman syndrome (AS) is a neurodevelopmental disorder arising from loss of maternal UBE3A function, characterized by intellectual disability, absent speech, ataxic gait, and epilepsy in 80-90% of patients. Neurologic management centers on early diagnosis, confirmation of the underlying genetic mechanism, and symptomatic treatment of the most disabling features, especially seizures. Seizure management remains symptomatic, guided by retrospective cohort data, caregiver surveys, and expert opinion in the absence of randomized controlled trials. This review systematically addresses the complete neurology-centered clinical management pathway for AS - from diagnostic recognition, neurodevelopmental and seizure characterization, delineation of characteristic EEG changes, differentiation from genetic mimickers, and identification of nonepileptic events that commonly mimic seizures, through pharmacotherapy selection, status epilepticus recognition and treatment, trigger prevention, and transition of care, to lifelong multisystem follow-up - while situating these principles within the rapidly shifting landscape of disease-modifying therapies now entering Phase 2 and 3 evaluation. Levetiracetam and clobazam are currently the favored first-line agents; valproate and clonazepam are efficacious but carry a more complex adverse-effect profile. Emerging reports describe cannabidiol oil use. The ketogenic and low hypoglycemic index diets offer adjunctive options for refractory cases. Three antisense oligonucleotide programs and the first gene replacement therapy have entered Phase 2/3 trials, marking a fundamental shift toward disease modification. Multidisciplinary, multisystem, lifelong care is essential, with careful attention to caregiver burden.